# Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients

> **NCT01641783** · PHASE2 · UNKNOWN · sponsor: **Yanqiao Zhang** · enrollment: 40 (estimated)

## Conditions studied

- Gastric Adenocarcinoma

## Interventions

- **DRUG:** nanoparticle Albumin-Bound paclitaxel

## Key facts

- **NCT ID:** NCT01641783
- **Lead sponsor:** Yanqiao Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-07
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2012-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01641783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01641783, "Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01641783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*